As previously reported yesterday, Guggenheim downgraded Outlook Therapeutics (OTLK) to Neutral from Buy and removed the firm’s price target after the company received another complete response letter from the FDA regarding their BLA resubmission for ONS-5010 for the treatment of wetAMD. The firm, which previously thought there was “a small chance of approval,” now has “serious doubts” on the company’s ability to get ONS-5010 approved in the U.S.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OTLK:
- Outlook Therapeutics downgraded at H.C. Wainwright
- Outlook CRL ‘a significant setback,’ doesn’t mean end for Lytenava, says Chardan
- Outlook Therapeutics downgraded to Neutral from Buy at Guggenheim
- Outlook Therapeutics’ resubmission for wet AMD candidate rejected by FDA
- Navigating Trade Turbulence: Outlook Therapeutics’ Struggle with Global Trade Policies